Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

Thehang LuuKyu-Pyo KimSuzette BlanchardBean AnyangArti HurriaLixin YangJan H BeumerGeorge SomloYun Yen

Published in: Breast cancer research and treatment (2017)

We established the MTD of vorinostat and ixabepilone. This drug combination offers a novel therapy for previously treated MBC patients. The potential for lower toxicity and comparable efficacy compared to current therapies warrants further study.

Keyphrases

metastatic breast cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
study protocol
oxidative stress
prognostic factors
histone deacetylase
risk assessment
human health
climate change